Five Prime Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference
Jan 06, 2016 21:05 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein...
Novavax to Present at the 34th Annual J.P. Morgan Healthcare Conference
Jan 06, 2016 21:02 pm UTC| Business
GAITHERSBURG, Md., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and...
Caladrius Tightens Strategic Focus and Provides 2016 Revenue Guidance
Jan 06, 2016 21:01 pm UTC| Business
Emphasizes PCT subsidiary’s leadership position in the emerging cell therapy market with expectations for 30% revenue growth in 2016 Focuses clinical development on innovative platform of immune modulation with T...
Spark Therapeutics Announces Addition of Lota Zoth to Its Board of Directors
Jan 06, 2016 21:01 pm UTC| Business
PHILADELPHIA, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics, Inc. (NASDAQ:ONCE) announced today that Lota Zoth, CPA, a long-time financial executive at multiple publicly listed companies, has been named to the...
Jan 06, 2016 21:01 pm UTC| Business
DEVON, Pa., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments,...
Mistras Group Announces Strong Second Quarter FY'16 Results and Raises Profit Guidance
Jan 06, 2016 21:01 pm UTC| Business
Record Earnings per Diluted Share of 39 cents for the QuarterAdjusted EBITDA of $29.1 Million, or 14.9% of Revenues for the QuarterProfit Improvements in International and Products Segments Exceed small Services...
Fate Therapeutics to Present at Biotech Showcase 2016
Jan 06, 2016 21:01 pm UTC| Business
SAN DIEGO, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and...